Collagen II hydrogel-mediated sustained delivery of lacosamide attenuates cartilage degeneration and pain in osteoarthritis - PubMed
3 days ago
- #Osteoarthritis
- #Collagen Hydrogel
- #Lacosamide
- Osteoarthritis (OA) lacks effective disease-modifying therapies.
- Nav1.7 identified as a dual-acting therapeutic target in OA, regulating chondrocyte metabolism and pain.
- Lacosamide (LCM) evaluated as a disease-modifying candidate with cartilage-targeted delivery.
- LCM showed superior efficacy in suppressing IL-1β-induced catabolism and promoting anabolism in human chondrocytes compared to other sodium channel inhibitors.
- Systemic and intra-articular LCM administration reduced cartilage degeneration and pain in murine OA models.
- Collagen II-based thermoresponsive hydrogel developed for sustained intra-articular delivery of LCM, enhancing joint retention and therapeutic durability.
- LCM increased HSP70 and midkine secretion, driving anabolic and anti-catabolic responses.
- LCM's clinical efficacy in Nav1.7 mutation-related neuropathy supports its translational potential as a dual-acting therapy for OA.